Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.64 |
| ▸ | HTR3B | O95264 | 3/20 | 0.64 |
| ▸ | HTR3A | P46098 | 3/20 | 0.64 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.64 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30818941 | 1.00 | HTR3E (0.64) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6843345 | 0.86 | GAA (0.59) | ALDH1A1KMT2ACYP1A2CYP2D6MEN1 | |
| SCHEMBL16334097 | 0.82 | HTR3E (0.70) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1810974 | 0.82 | HTR3E (0.70) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16333725 | 0.81 | HTR3E (0.68) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL27643869 | 0.79 | HTR3A (0.66) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL26220995 | 0.79 | HTR3A (0.71) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL22334883 | 0.79 | GAA (0.53) | ALDH1A1ALOX15TSHRMAPTGAA | |
| SCHEMBL21154003 | 0.79 | KMT2A (0.51) | HTR3AALDH1A1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL2371248 | 0.78 | GAA (0.51) | ALDH1A1TSHRMAPTGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265086-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | NEUROPORE THERAPIES, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| EP-3565810-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018127801-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-07-12 | — | — | WO | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| CN-102516165-A | Substituted pyridine derivatives | LUNDBECK & CO AS H | 2012-06-27 | — | — | CN | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2008082490-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-0334146-A1 | Morpholines and morpholine-N-oxides, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1989-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | HTR3E 3680/4885HTR3B 2491/4885HTR3A 2931/4885 |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | HTR3E 4234/4885HTR3B 4124/4885HTR3A 4110/4885 |
| US-20230265086-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | ATG7, ULK1, BECN1 | HTR3E 755/4885HTR3B 694/4885HTR3A 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.